Rice Hall James & Associates LLC purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 62,451 shares of the company's stock, valued at approximately $2,723,000. Rice Hall James & Associates LLC owned approximately 0.14% of Omnicell as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently bought and sold shares of OMCL. Nisa Investment Advisors LLC increased its position in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock worth $38,000 after buying an additional 1,000 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after purchasing an additional 553 shares during the period. EntryPoint Capital LLC grew its position in shares of Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company's stock valued at $72,000 after purchasing an additional 1,345 shares during the period. CWM LLC grew its position in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company's stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. grew its position in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock valued at $96,000 after purchasing an additional 1,542 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently commented on OMCL. Craig Hallum lifted their price objective on Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday. Barclays lifted their price objective on Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a report on Saturday, October 19th. Benchmark reiterated a "buy" rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, Bank of America reiterated a "neutral" rating and issued a $57.00 target price (up previously from $44.00) on shares of Omnicell in a report on Thursday. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $49.14.
Get Our Latest Research Report on OMCL
Omnicell Stock Up 0.1 %
Shares of OMCL traded up $0.03 during midday trading on Friday, reaching $48.67. 683,792 shares of the company were exchanged, compared to its average volume of 500,369. The stock has a 50-day moving average price of $43.34 and a 200-day moving average price of $35.38. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -124.79, a P/E/G ratio of 53.62 and a beta of 0.81. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a current ratio of 1.05, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million for the quarter, compared to analysts' expectations of $254.41 million. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The firm's quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 earnings per share. Research analysts expect that Omnicell, Inc. will post 0.64 earnings per share for the current year.
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
